{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:09:28Z","timestamp":1790273368810,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01020-z","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:37:10Z","timestamp":1790271430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Rozanolixizumab with Efgartigimod or Intravenous Immunoglobulin in Generalized Myasthenia Gravis Using Matching Adjusted Indirect Comparisons"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4632-6097","authenticated-orcid":false,"given":"Vikalp","family":"Maheshwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhiroop","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitender","family":"Takyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arju","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"21","key":"1020_CR1","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.3390\/jcm11216394","volume":"11","author":"D S\u00e1nchez-Tejerina","year":"2022","unstructured":"S\u00e1nchez-Tejerina D, Sotoca J, Llaurado A, et al. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med. 2022;11(21):6394.","journal-title":"J Clin Med"},{"key":"1020_CR2","unstructured":"NIH. Myasthenia gravis. 2024. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/myasthenia-gravis. Accessed November 2025"},{"key":"1020_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00408-x","author":"K Jackson","year":"2022","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2022. https:\/\/doi.org\/10.1007\/s40120-022-00408-x.","journal-title":"Neurol Ther"},{"key":"1020_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1020_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39(2):185\u2013213.","journal-title":"BioDrugs"},{"issue":"8","key":"1020_CR6","first-page":"1637","volume":"18","author":"LN Zhu","year":"2023","unstructured":"Zhu LN, Hou HM, Wang S, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637\u201344.","journal-title":"Neural Regen Res"},{"issue":"23","key":"1020_CR7","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"5","key":"1020_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase\u00a03 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"key":"1020_CR9","unstructured":"ClinicalTrials.gov (NCT03971422), UCB Biopharma SRL., A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis. 2019. https:\/\/clinicaltrials.gov\/study\/NCT03971422. Accessed November 2025."},{"key":"1020_CR10","unstructured":"ClinicalTrials.gov (NCT03669588), Argenx., An efficacy and safety study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness (ADAPT). https:\/\/clinicaltrials.gov\/study\/NCT036695882018. Accessed November 2025."},{"issue":"12","key":"1020_CR11","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"key":"1020_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, et al. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol. 2023;14:1280226.","journal-title":"Front Immunol"},{"issue":"2","key":"1020_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, Qi W, Hao L, Guo X. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2024;38(2):93\u2013104.","journal-title":"CNS Drugs"},{"issue":"6","key":"1020_CR14","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","volume":"41","author":"C van Steen","year":"2024","unstructured":"van Steen C, Celico L, Spaepen E, et al. Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison. Adv Ther. 2024;41(6):2486\u201399.","journal-title":"Adv Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01020-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:37:14Z","timestamp":1790271434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01020-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":14,"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01020-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carolina Barnett Tapia has served as member of the advisory board for argenx, Alexion, UCB, Janssen and NMD Pharma. She has been a consultant for argenx, Janssen, Novartis and UCB. She has received research support from US Department of Defense, Muscular Dystrophy Canada and MGNet. She is the primary developer of the MGII and may receive royalties. Saiju Jacob has served as an international advisory board member for Alexion, Alnylam, argenx, Immunovant, Johnson and Johnson, Merck, Novartis, Regeneron and UCB; is currently an expert panel member of the Myasthenia Gravis consortium for argenx and UCB; and has received speaker fees from Terumo BCT and Eisai Pharmaceuticals. April Betts is employed by UCB. Vikalp Maheshwari, Abhiroop Chakravarty, Jitender Takyar and Arju Dhawan are employed by Parexel International, which was hired by UCB Pharma to collaborate on this study.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}